CORRELATE-UK
Research type
Research Study
Full title
CORRELATE-UK: COnsistency of Response with RimegEpant oral Lyophilisate in Acute Treatment of migrainE
IRAS ID
342561
Contact name
Giorgio Lambru
Contact email
Sponsor organisation
Pfizer Ltd
Duration of Study in the UK
0 years, 9 months, 1 days
Research summary
Rimegepant is a migraine medication manufactured by Pfizer, the sponsor of the present study, which has been tested in clinical trials and is approved for use in the United Kingdom (UK) for treating migraine symptoms. Further evidence is needed on the effectiveness of rimegepant in treating multiple migraine attacks when it is taken in a real-world setting.
This study aims to identify whether patients taking rimegepant consider it to be effective in treating multiple migraines over 12 weeks. The study will measure improvement in pain and non-pain symptoms, as well as the ability to return to normal activities.UK-based adults who have been prescribed rimegepant for treating migraine symptoms will be eligible to take part in the study. Patients will be informed about the study by the doctors who are treating their migraines. Participants will then register, provide consent for, and take part in the study via a web application. When participants first join the study, they will be asked to provide data about themselves, their history with migraines, and their migraine treatment. Daily and over the course of 12 weeks, participants will be asked whether they have had migraine symptoms. If they respond yes, participants will complete follow-up questions about their migraine symptoms and treatment. On the final day of the study, participants will complete a set of surveys about their overall satisfaction with their migraine treatment.
Data from the study will support doctors and patients in making informed decisions on the use of rimegepant for treating migraine symptoms.
REC name
HSC REC B
REC reference
25/NI/0048
Date of REC Opinion
2 Apr 2025
REC opinion
Further Information Favourable Opinion